340B Drug Pricing Program
AHA, others file amicus brief against Novartis motion to block Rhode Island 340B Contract Pharmacy Law -9-16-2025.
AHA, others file amicus brief against AbbVie’s motion to block Rhode Island’s 340B Contract Pharmacy Law-9-18-2025.
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s estimates, and HRSA should delay the program’s implementation, the AHA today told the agency.
In a letter responding to HRSA’s information collection request regarding the expected costs of its 340B Rebate Model Pilot Program, the AHA said 340B hospitals indicated that the operational costs associated with the rebate model could range from $150,000 to over $500,000 per hospital.
AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements.
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements. In particular, the court held that “Plaintiffs have failed…
AHA 340B Advocacy Alliance Bulletin - September 16, 2025.
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical center payment system proposed rule.
AHA, others file amicus brief opposing AbbVie’s motion for preliminary injunction against enforcement of Maine’s 340B contract pharmacy law.